Int'l : +1(646) 600-5072 | query@kbvresearch.com
Published Date : 20-11-2018 | Pages: 77 | Formats: PDF |
The North America Cancer Immunotherapy Market would witness market growth of 13.1% CAGR during the forecast period (2018 – 2024). Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.
Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user.
Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd
Scope of the Study
Market Segmentation:
By Technology
By Application
By End User
By Country
Companies Profiled
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Cancer Immunotherapy Market, by Technology
1.4.2 North America Cancer Immunotherapy Market, by Application
1.4.3 North America Cancer Immunotherapy Market, by End User
1.4.4 North America Cancer Immunotherapy Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Cancer Immunotherapy Market by Technology
3.1.1 North America Monoclonal Antibodies Cancer Immunotherapy Market by Country
3.1.2 North America Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
3.1.3 North America Other Technology Cancer Immunotherapy Market by Country
Chapter 4. North America Cancer Immunotherapy Market by Application
4.1.1 North America Cancer Immunotherapy Lung Cancer Market by Country
4.1.2 North America Cancer Immunotherapy Breast Cancer Market by Country
4.1.3 North America Cancer Immunotherapy Colorectal Cancer Market by Country
4.1.4 North America Cancer Immunotherapy Melanoma Market by Country
4.1.5 North America Cancer Immunotherapy Prostate Cancer Market by Country
4.1.6 North America Cancer Immunotherapy Head & Neck Cancer Market by Country
4.1.7 North America Other Application Cancer Immunotherapy Market by Country
Chapter 5. North America Cancer Immunotherapy Market by End User
5.1.1 North America Hospitals Cancer Immunotherapy Market by Country
5.1.2 North America Clinics Cancer Immunotherapy Market by Country
5.1.3 North America Other End User Cancer Immunotherapy Market by Country
Chapter 6. North America Cancer Immunotherapy Market by Country
6.1 US Cancer Immunotherapy Market
6.1.1 US Cancer Immunotherapy Market by Technology
6.1.2 US Cancer Immunotherapy Market by Application
6.1.3 US Cancer Immunotherapy Market by End User
6.2 Canada Cancer Immunotherapy Market
6.2.1 Canada Cancer Immunotherapy Market by Technology
6.2.2 Canada Cancer Immunotherapy Market by Application
6.2.3 Canada Cancer Immunotherapy Market by End User
6.3 Mexico Cancer Immunotherapy Market
6.3.1 Mexico Cancer Immunotherapy Market by Technology
6.3.2 Mexico Cancer Immunotherapy Market by Application
6.3.3 Mexico Cancer Immunotherapy Market by End User
6.4 Rest of North America Cancer Immunotherapy Market
6.4.1 Rest of North America Cancer Immunotherapy Market by Technology
6.4.2 Rest of North America Cancer Immunotherapy Market by Application
6.4.3 Rest of North America Cancer Immunotherapy Market by End User
Chapter 7. Company Profiles
7.1 Amgen Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental & Regional Analysis
7.1.4 Research and Development Expense
7.2 Merck & Company, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional and Segmental Analysis
7.2.4 Research & Development
7.3 Pfizer Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Revenue analysis by Region
7.3.5 Research and Development
7.4 Immunomedics Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Revenue Analysis by Region
7.4.4 Research and Development
7.5 Astrazeneca Plc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental analysis
7.5.4 Research & Development
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Revenue & Segment analysis
7.6.4 Research and Development
7.7 Eli Lilly and Company
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Bristol-Myers Squibb Company
7.9.1 Company Overview
7.1 Bayer AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
TABLE 1 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 2 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 3 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 4 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 5 NORTH AMERICA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 6 NORTH AMERICA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 7 NORTH AMERICA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 8 NORTH AMERICA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 9 NORTH AMERICA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 10 NORTH AMERICA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 11 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 12 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 13 NORTH AMERICA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 14 NORTH AMERICA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 15 NORTH AMERICA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 16 NORTH AMERICA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 17 NORTH AMERICA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 18 NORTH AMERICA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 19 NORTH AMERICA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 20 NORTH AMERICA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 21 NORTH AMERICA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 22 NORTH AMERICA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 23 NORTH AMERICA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 24 NORTH AMERICA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 25 NORTH AMERICA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 26 NORTH AMERICA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 27 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 28 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 29 NORTH AMERICA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 30 NORTH AMERICA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 31 NORTH AMERICA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 32 NORTH AMERICA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 33 NORTH AMERICA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 34 NORTH AMERICA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 35 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 36 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 37 US CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 38 US CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 39 US CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 40 US CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 41 US CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 42 US CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 43 US CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 44 US CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 45 CANADA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 46 CANADA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 47 CANADA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 48 CANADA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 49 CANADA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 50 CANADA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 51 CANADA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 52 CANADA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 53 MEXICO CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 54 MEXICO CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 55 MEXICO CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 56 MEXICO CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 57 MEXICO CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 58 MEXICO CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 59 MEXICO CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 60 MEXICO CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 61 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 62 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 63 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 64 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 65 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 66 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 67 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 68 REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 69 KEY INFORMATION-AMGEN INC.
TABLE 70 KEY INFORMATION-MERCK & COMPANY INC.
TABLE 71 KEY INFORMATION- PFIZER INC.
TABLE 72 KEY INFORMATION- IMMUNOMEDICS INC.
TABLE 73 KEY INFORMATION- ASTRAZENECA PLC.
TABLE 74 KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.
TABLE 75 KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 76 KEY INFORMATION – NOVARTIS AG
TABLE 77 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
TABLE 78 KEY INFORMATION – BAYER AG